AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Coatomer subunit zeta-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P61923

UPID:

COPZ1_HUMAN

Alternative names:

Zeta-1-coat protein

Alternative UPACC:

P61923; B4DDX8; B4DHZ0; F8VS17; F8VWL5; Q549N6; Q9Y3C3

Background:

The Coatomer subunit zeta-1, also known as Zeta-1-coat protein, plays a pivotal role in cellular transport mechanisms. It is a part of the coatomer complex, essential for the transport of biosynthetic proteins from the ER through the Golgi apparatus to the trans Golgi network. This protein binds to dilysine motifs and is crucial for the budding from Golgi membranes, facilitating the retrograde Golgi-to-ER transport of dilysine-tagged proteins.

Therapeutic significance:

Understanding the role of Coatomer subunit zeta-1 could open doors to potential therapeutic strategies. Its involvement in protein transport processes makes it a significant target for research aimed at uncovering novel drug discovery avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.